$EDIT Up 19%! 🚀 🔹 Editas Medicine catching strong momentum as gene-editing names heat up 📈 🔹 Clinical-stage biotech focused on CRISPR-based genomic medicine

$EDIT Up 19%! 🚀 🔹 Editas Medicine catching strong momentum as gene-editing names heat up 📈 🔹 Clinical-stage biotech focused on CRISPR-based genomic medicines for serious diseases 🧬 🔹 Recent investor focus on EDIT-401, its in vivo cholesterol-lowering program targeting PCSK9 🔥 🔹 Company also …